10-K/A: Carisma Therapeutics Files Amendment to 10-K, Providing Detailed Insight into Executive Compensation and Corporate Governance
10-K/A Amendment
Carisma Therapeutics files an amendment to its 2024 Annual Report on Form 10-K, including detailed information on directors, executive compensation, corporate governance, and related matters omitted from the original filing.
Summary
- Carisma Therapeutics Inc. filed Amendment No. 1 on Form 10-K/A to its Annual Report for the year ended December 31, 2024.
- The amendment includes information required by Part III of Form 10-K, which was omitted from the original filing.
- The company is updating certain exhibits that were filed in the original filing.
- The document details the company's directors, executive officers, and corporate governance practices.
- Executive compensation, including salaries, bonuses, and equity incentives, is disclosed for named executive officers (NEOs).
- The amendment also covers security ownership, related party transactions, and principal accountant fees and services.
- The company's insider trading policy and compensation recovery (clawback) policy are also addressed.
- Director compensation, including fees and equity awards, is outlined.
- The document includes information about the company's equity compensation plans, including the 2014 Plan and the 2017 Plan.
- The amendment includes new certifications by the principal executive officer and principal financial officer.
Sentiment
Score: 6
Explanation: The document is primarily factual and descriptive, providing information on compensation, governance, and ownership. The sentiment is neutral, with no strong positive or negative indicators.
Positives
- The company has established audit, compensation, nominating and corporate governance, and science committees.
- The board of directors has determined that Marella Thorell is an audit committee financial expert.
- The company has adopted a written code of business conduct and ethics.
- The company has adopted an insider trading policy and a Dodd-Frank Compensation Recovery Policy (Clawback Policy).
- The company maintains a 401(k) plan with a matching policy for employee contributions.
Negatives
- Richard Morris, the former Chief Financial Officer, ceased providing services to the Company on December 31, 2024, in connection with the company's previously announced reduction in force.
Risks
- The document does not explicitly detail risks, but the company's reliance on key personnel and the competitive nature of the biopharmaceutical industry could be considered inherent risks.
Future Outlook
The company expects that its compensation committee will continue to engage independent compensation consultants to provide additional guidance on its executive and director compensation programs and to conduct further competitive benchmarking against a peer group of publicly traded companies.
Industry Context
The document provides insight into the compensation and governance practices of a publicly traded biopharmaceutical company, which is useful for comparing to industry standards and peer companies.
Comparison to Industry Standards
- The document does not provide specific comparisons to industry standards.
- However, it mentions using compensation data from comparable publicly traded companies in the biotechnology and biopharmaceutical industry for benchmarking.
- The peer group is based on industry, market capitalization, headcount, and location.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Vice President of Finance | NA | Natalie McAndrew | January 2025 | NA |
| Chief Financial Officer | Richard Morris | NA | December 31, 2024 | Reduction in force |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Board Committee Composition | Details of the members of the audit committee, compensation committee, nominating and corporate governance committee and science committee. | N/A | Ensures compliance with regulatory requirements and promotes effective oversight. |
| Director Compensation Policy | Modifications to the director compensation policy, including increases to the Initial Option and Annual Option awards, effective January 1, 2025. | January 1, 2025 | May impact director recruitment and retention. |
Related Party Transactions
- The document describes related person transactions since January 1, 2023, including a private placement of securities and a Legacy Carisma Stockholders Registration Rights Agreement.
- The pre-closing financing involved the issuance of Legacy Carisma common stock to directors, executive officers, and holders of more than 5% of the company's voting securities and their affiliates.
Stakeholder Impact
- Shareholders: Information on security ownership and equity compensation plans.
- Employees: Details on executive compensation and 401(k) plan.
- Directors: Information on director compensation and independence.
Key Dates
| Date | Description |
|---|---|
| February 25, 2008 | Original Certificate of Incorporation filed as Newco LS14, Inc. |
| February 11, 2014 | Certificate of Incorporation amended and restated. |
| March 7, 2023 | Restated Certificate of Incorporation filed, changing name to Carisma Therapeutics Inc. and Merger closing date. |
| March 7, 2023 | Steven Kelly appointed President and Chief Executive Officer, Richard Morris appointed Chief Financial Officer, and Michael Klichinsky appointed Chief Scientific Officer. |
| March 7, 2023 | Legacy Carisma Stockholders Registration Rights Agreement. |
| June 6, 2023 | Certificate of Amendment to Restated Certificate of Incorporation. |
| October 2, 2023 | Dodd-Frank Compensation Recovery Policy (the Clawback Policy) effective date. |
| December 7, 2024 | Company notified Mr. Morris that his employment with the Company would terminate without Cause effective December 31, 2024. |
| December 31, 2024 | Richard Morris ceased providing services to the Company. |
| January 1, 2025 | Steven Kelly's and Michael Klichinsky's annual base compensation increased. |
| March 31, 2025 | Date for director and executive officer information. |
| April 29, 2025 | Date of Amendment No. 1 on Form 10-K/A filing. |
Keywords
executive compensation, corporate governance, directors, stock options, biopharmaceutical, Carisma Therapeutics, Form 10-K/A, financial reporting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.